Greater Cannabis Company Inc. (OTCMKTS:GCAN) Stock Surges 8%: What’s The Buzz?
Greater Cannabis Company Inc. (OTCMKTS:GCAN) was up 8% after the biopharmaceutical company creating cannabinoid therapeutics announced the appointment of Dr. Adi Aran as the Head of Paediatric Neurology at Shaare Zedek Medical center to spearhead research and development initiatives for unique product formulas.
Market Stats
On Thursday, GCAN stock moved up 8.33% at $0.0026 with more than 5.10 million shares, compared to its average volume of 2.58 million shares. The stock has moved within a range of $0.0024 – 0.0028 after opening trading at $0.0026.
Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor
Aran is a reputable key opinion leader, a physician-scientist and cannabinoid neuropsychiatric therapeutics inventor licensed from Shaare Zedek Scientific Ltd. He is also Shaare Zedek Medical Centre’s Pediatric Neurology Director in Jerusalem.
Aran pioneered cannabinoids study in autistic children, and he specializes in Autism Spectrum Disorder diagnosis and treatment. His work focuses on endocannabinoid system involvement in genetic disorders and ASD and the study of new therapies to treat these disorders. GCANRx CEO Aitan Zacharin said that Aran has strategic expertise with vast experience in pioneering cannabinoid research, which will be valuable to the company as it advances its operations.Zacharin added that they are delighted that Aran has joined the company to make an impact on seeking solutions for unmet medical needs. Therefore GCAN is worth watching.
Traders Corner
GCAN stock is below the 20-Day and 50-Day Moving averages of $0.0043 and $0051 respectively. The stock is trading in the oversold zone with the RSI at 30. The stock is down 50% in the past month.
